A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.
Summary
In a phase 3, double-blind RCT of 498 untreated ES-SCLC patients, socazolimab plus carboplatin/etoposide improved overall survival (13.9 vs 11.6 months; HR 0.799) and progression-free survival (5.55 vs 4.37 months; HR 0.569) versus placebo plus chemotherapy, with no excess severe toxicity. These results support socazolimab as a first-line option in ES-SCLC.
Key Findings
- Overall survival improved to 13.90 months vs 11.58 months; HR 0.799 (95% CI 0.652–0.979; p=0.0158).
- Progression-free survival improved to 5.55 months vs 4.37 months; HR 0.569 (95% CI 0.457–0.708; p<0.0001).
- Grade ≥3 treatment-related adverse events: 80.3% (socazolimab) vs 75.7% (placebo), indicating no excess safety risk.
Clinical Implications
Socazolimab plus carboplatin/etoposide may be considered a first-line regimen for ES-SCLC. Comparative effectiveness versus atezolizumab or durvalumab-based regimens and global generalizability require further study.
Why It Matters
Demonstrates a clinically meaningful OS benefit in first-line ES-SCLC with an immune checkpoint inhibitor, potentially influencing treatment standards, especially where access to current PD-L1 inhibitors varies.
Limitations
- Conducted exclusively in China; generalizability to other populations needs confirmation.
- No head-to-head comparison with current PD-L1 inhibitors used globally (e.g., atezolizumab, durvalumab).
Future Directions
Head-to-head trials against existing PD-(L)1-based regimens, biomarker analyses to identify responders, and real-world effectiveness across diverse healthcare systems.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Phase 3 randomized, double-blind, placebo-controlled trial demonstrating survival benefit.
- Study Design
- OTHER